Gefitinib vs tri‐weekly paclitaxel plus carboplatin
Progression‐free survival · EGFR M+ patients with NSCLC
Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).
1 finding from 1 review
- First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes onlyHR 0.39 [0.32, 0.48]2 studies · 485 participantsHigh